Launch week offerEnds in00h00m00s

annual Promonthly Pro

Mikko Niemi

Professor

University of Helsinki

Finland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Finland

About

Mikko Niemi is an Assistant Professor at the Department of Clinical Pharmacology, University of Helsinki, located in Helsinki, Finland. His research encompasses various areas, including pharmacogenomics, pharmacokinetics, and drug transport mechanisms, as evidenced by his recent articles on cytochrome P450 enzymes and statin pharmacokinetics. He has contributed significantly to understanding the genetic variants affecting drug metabolism and personalized medicine.

Articles (32)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (32)

Mark van Gils

Professor of Digital Healthcare, principal investigator of research group Decision Support for Health

University of Tampere

FINLAND

Mikko Niemi

Research Interests

Make your next move.

Explore related searches

About

Articles (32)

Effects of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacological Effects of Orally Administered Tramadol: A Randomised Controlled Trial

Repeated Intake of Grapefruit Juice Inhibits CYP2B6, CYP2C9, CYP2C19, and CYP3A4 while Lingonberry Powder Does Not Induce Major CYP Enzymes in Humans

Novel inhibitors of BCRP found among drugs used in the treatment of cancer

Systematic evaluation of propofol population pharmacokinetic models and development of a literature-supported new meta-model for critically ill preterm and term neonates

A Phenotyping Tool for Seven Cytochrome P450 Enzymes and Two Transporters: Application to Examine the Effects of Clopidogrel and Gemfibrozil

Identification of Genetic Variants Associated with Pravastatin and Pitavastatin Pharmacokinetics

Reduced dose direct oral anticoagulants and time-in-therapeutic-range defined warfarin in new-onset atrial fibrillation: a report from the nationwide FinACAF study

Transport of statins by multidrug resistance-associated proteins 1 and 5

In vitro characterization of SLCO2B1 genetic variants

Genetic and Functional Characterization of DPYD Exon 4 Deletion Common in the Finnish Population

Efflux and uptake transport and gut microbial reactivation of raloxifene glucuronides

Non‐targeted metabolomics for the identification of plasma metabolites associated with organic anion transporting polypeptide <scp>1B1</scp> function

Time-in-therapeutic-range defined warfarin and direct oral anticoagulants in atrial fibrillation: a Nationwide Cohort Study

Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity

Ticagrelor modestly raises plasma riboflavin concentration in humans and inhibits riboflavin transport by BCRP and MRP4

Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes – detailed studies on CYP3A inhibitors

Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin

Genome‐Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP

Posaconazole‐ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment

Candesartan Has No Clinically Meaningful Effect on the Plasma Concentrations of Cytochrome P450 2C8 Substrate Repaglinide in Humans

Population Pharmacokinetic Quantification of CYP2D6 Activity in Codeine Metabolism in Ambulatory Surgical Patients for Model-Informed Precision Dosing

CYP3A4*22 may increase bleeding risk in ticagrelor users

Rhabdomyolysis during concomitant ticagrelor and rosuvastatin

Functional Characterization of Six SLCO1B1 (OATP1B1) Variants Observed in Finnish Individuals with a Psychotic Disorder

The Sixth European Society of Pharmacogenomics and Personalised Therapy Congress

Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors

Toxicity and therapy outcome associations in LIG3, SLCO1B3, ABCB1, OPRM1 and GSTP1 in high‐grade serous ovarian cancer

Drug‐related deaths in a university hospital: Comparison to previous decades

CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel.

Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.

The effect of hydroxychloroquine on cholesterol metabolism in statin treated patients after myocardial infarction.

Characterization of Bile Acid Sulfate Conjugates as Substrates of Human Organic Anion Transporting Polypeptides

Collaborators (32)

Mark van Gils

Stefan Oswald

Klaus Olkkola

Olli Kampman

Feng Deng

Kaisa Huhtinen

Aapo Aro

Anna-Leena Vuorinen

Erkki Isometsä

Noora Sjöstedt

Janne Tapio Backman

Aleksi Tornio

Aarno Palotie

Lea Urpa

Heidi Kidron

Anssi Mykkänen

Marie-Noëlle PALUDETTO

Mika Lehto

Marko Lehtonen

Olli Halminen

Pertti Neuvonen

Johanna Sistonen

Sampsa Hautaniemi

Johanna Hynninen

Jari Tiihonen

Wilma Kiander

Anne Filppula

Outi Lapatto‐Reiniluoto

Markus Otto Hjalmar Ramste

Tuija Tapaninen

Eeva Moilanen

Jesse Swen

Make your next move.